Study on Bioequivalence of Flunarizine Capsules in Healthy Volunteers
Yu Liu
Abstract
Yu Liu
Abstract
A single administration of 20mg domestic and reference flunarizine capsules were given to two group of 20 healthy male volunteers in randomized crossover study respectively. A high performance liquid chromatographic assay with fluorimetric detection was developed to determine the concentration of flunarizine in human serum. The data were analyzed by 3P97 program. The pharmacokinetics parameters after a single oral administration of 20mg domestic and reference products were as follows: Cmax54.75±14.52μg.L-(-1)and 52.20±13.04μg.L-(-1);tmax2.40±0.45 h and 2.33±0.44h; AUC_(0-24)256.56±42.32μg.L-(-1).hand 248.81±37.43μg.h.L-(-1); AUC_(0-∞)275.87± 45.62μg.h.L-(-1)and 267.48±40.10μg.h.L-(-1);respectively. Variance analysis and two one-sided test were performed to palameters: Cmax AUC_(0-24)andAUC_(0-∞)There was no significant difference. The two preparations were of bioequivalence, the relative bioavailabilities of single oral administration group was 103.29±9.36%.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
A single administration of 20mg domestic and reference flunarizine capsules were given to two group of 20 healthy male volunteers in randomized crossover study respectively. A high performance liquid chromatographic assay with fluorimetric detection was developed to determine the concentration of flunarizine in human serum. The data were analyzed by 3P97 program. The pharmacokinetics parameters after a single oral administration of 20mg domestic and reference products were as follows: Cmax54.75±14.52μg.L-(-1)and 52.20±13.04μg.L-(-1);tmax2.40±0.45 h and 2.33±0.44h; AUC_(0-24)256.56±42.32μg.L-(-1).hand 248.81±37.43μg.h.L-(-1); AUC_(0-∞)275.87± 45.62μg.h.L-(-1)and 267.48±40.10μg.h.L-(-1);respectively. Variance analysis and two one-sided test were performed to palameters: Cmax AUC_(0-24)andAUC_(0-∞)There was no significant difference. The two preparations were of bioequivalence, the relative bioavailabilities of single oral administration group was 103.29±9.36%.
Key concepts: Bioequivalence, Cmax, Pharmacokinetics, Crossover study, Flunarizine, Pharmacology, Oral administration, Medicine